HGFR Peptide
€100.00
In stock
SKU
350475
Protein Family: Enzymes, Protein Kinases, Receptors and Channels
Pathway and Disease: Cancers, Cell Communication, Development and Behavior, Infectious Diseases, Signaling Molecules and Interaction
Alternate Names: Hepatocyte growth factor receptor; HGF receptor; Scatter factor receptor; SF receptor; HGF/SF receptor; Met proto-oncogene tyrosine kinase; c-Met
Accession No.: P08581, NP_000236
Description:
HGFR (MET), a tyrosine protein kinase, is the receptor for the hepatocyte growth factor and scater factor. Activation of HGFR after rearrangement with the TPR gene produces an oncogenic protein c-MET. Defects in HGFR/MET are a cause of hepatocellular carcinoma and renal carcinoma.
Format:
Each vial contains 0.1 ml peptide in deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1987.3 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200113 is selected from a sequence within the N-term region of human HGFR. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C83H139N23O27S3
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease: Cancers, Cell Communication, Development and Behavior, Infectious Diseases, Signaling Molecules and Interaction
Alternate Names: Hepatocyte growth factor receptor; HGF receptor; Scatter factor receptor; SF receptor; HGF/SF receptor; Met proto-oncogene tyrosine kinase; c-Met
Accession No.: P08581, NP_000236
Description:
HGFR (MET), a tyrosine protein kinase, is the receptor for the hepatocyte growth factor and scater factor. Activation of HGFR after rearrangement with the TPR gene produces an oncogenic protein c-MET. Defects in HGFR/MET are a cause of hepatocellular carcinoma and renal carcinoma.
Format:
Each vial contains 0.1 ml peptide in deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1987.3 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200113 is selected from a sequence within the N-term region of human HGFR. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C83H139N23O27S3
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
| Is Featured? | No |
|---|
Write Your Own Review